-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Pharmaceutical Guanlan
Recently, the official website of the American Society of Clinical Oncology (ASCO) annual meeting officially announced the abstract of the 2021 ASCO conference.
1.
1.
Mechanism of action: anti-PD-1 monoclonal antibody
Research information: A randomized, double-blind, placebo-controlled Phase 3 clinical study (ESCORT-1st) to evaluate carrelizumab combined with chemotherapy versus chemotherapy for untreated advanced or metastatic esophageal squamous cells Effect for cancer patients
Research information: A randomized, double-blind, placebo-controlled Phase 3 clinical study (ESCORT-1st) to evaluate carrelizumab combined with chemotherapy versus chemotherapy for untreated advanced or metastatic esophageal squamous cells Effect for cancer patientsResearch leader: Professor Xu Ruihua, Sun Yat-sen University Cancer Center
Research leader: Professor Xu Ruihua, Sun Yat-sen University Cancer CenterFrom December 3, 2018 to May 12, 2020, 596 patients received randomization.
In the study, the incidence of ≥ grade 3 treatment-related adverse reactions in the two groups was similar (63.
2.
2.
Mechanism of action: anti-PD-1 monoclonal antibody
Research information: A randomized controlled, double-blind, multi-center phase 3 clinical trial (CAPTAIN-1st) to evaluate the effect of carrelizumab combined with gemcitabine and cisplatin in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma
Research information: A randomized controlled, double-blind, multi-center phase 3 clinical trial (CAPTAIN-1st) to evaluate the effect of carrelizumab combined with gemcitabine and cisplatin in the first-line treatment of recurrent/metastatic nasopharyngeal carcinomaResearch leader: Professor Zhang Li, Sun Yat-sen University Cancer Center
Research leader: Professor Zhang Li, Sun Yat-sen University Cancer CenterFrom November 2018 to November 2019, 263 patients from 28 centers were randomly assigned to carrelizumab + GP (gemcitabine + cisplatin) group (n=134, carrelizumab group) ) Or placebo+GP group (n=129, placebo group).
In terms of side effects, the incidence of ≥3 treatment-related adverse events (TRAEs) was 93% in the carrelizumab group and 90% in the placebo group.
3.
3.
Mechanism of action: CDK4/6 inhibitor
Research information: A multi-center, randomized, phase 3 study (DAWNA-1) to evaluate the effect of dapicilil versus placebo plus fulvestrant in the treatment of HR+/HER2-advanced breast cancer that has relapsed or progressed from previous endocrine therapy
Research information: A multi-center, randomized, phase 3 study (DAWNA-1) to evaluate the effect of dapicilil versus placebo plus fulvestrant in the treatment of HR+/HER2-advanced breast cancer that has relapsed or progressed from previous endocrine therapyResearch leader: Professor Xu Binghe, Cancer Hospital of Chinese Academy of Medical Sciences, National Cancer Center
Research leader: Professor Xu Binghe, Cancer Hospital of Chinese Academy of Medical Sciences, National Cancer Center361 patients were randomized to receive dapiciride + fulvestrant (n=241, dapiciride group) or placebo + fulvestrant (n=120, placebo group) treatment.
The most common grade 3 or 4 AEs in the dapicillide group were neutropenia (84.
Four, famitinib + carrelizumab
Four, famitinib + carrelizumabMechanism of action: multi-target tyrosine kinase inhibitor, anti-PD-1 monoclonal antibody
Mechanism of action: multi-target tyrosine kinase inhibitor, anti-PD-1 monoclonal antibodyResearch information: A prospective, one-arm, phase 2 study (FUTURE-C-plus) to evaluate famitinib combined with carrelizumab + albumin paclitaxel in the first-line treatment of immunomodulated advanced triple-negative breast cancer Effect
Research information: A prospective, one-arm, phase 2 study (FUTURE-C-plus) to evaluate famitinib combined with carrelizumab + albumin paclitaxel in the first-line treatment of immunomodulated advanced triple-negative breast cancer EffectResearch leader: Professor Shao Zhimin, Fudan University Affiliated Cancer Hospital
Research leader: Professor Shao Zhimin, Fudan University Affiliated Cancer HospitalFrom October 2019 to October 2020, a total of 48 patients were enrolled.
Grade 3 or 4 adverse events were neutropenia, anemia, febrile neutropenia, thrombocytopenia, hypertension, hypothyroidism, proteinuria, sepsis, and immune-related myocarditis.
Five, SHR-1701
Five, SHR-1701Mechanism of action: PD-L1/TGF-β double antibody
Mechanism of action: PD-L1/TGF-β double antibodyResearch information: A phase 1 study exploring the treatment of SHR-1701 in patients with advanced solid tumors
Research information: A phase 1 study exploring the treatment of SHR-1701 in patients with advanced solid tumorsResearch leader: Professor Lin Shen, Peking University Cancer Hospital
Research leader: Professor Lin Shen, Peking University Cancer HospitalSeventeen cases were included in the dose-climbing stage.
PK analysis showed that SHR-1701 has a linear relationship with dose exposure in the dose range of 1-30mg/kg.
Peripheral blood PD-L1 occupancy rate exceeded 90% in all dose groups, and TGF-β1 capture was almost detected in all dose groups.
Of 49 patients, 45 patients completed at least one efficacy evaluation.
The ORR was 17.
8%, and 8 patients achieved partial remission (PR).
The disease control rate (DCR) is 40.
0%.
Most PR patients are still responding (7/8), and the median DoR has not yet been reached.
Based on safety, PK, PD, and efficacy data, the study recommends 30mg/kg Q3W (use once every 3 weeks) as the recommended dose for the Phase 2 study (RP2D).
Reference materials:
[1] Hengrui's original research shines on the world stage, and a number of blockbuster studies are shortlisted for the Oral session of the ASCO annual meeting.
Retrieved May 25, 2021, from https://mp.
weixin.
qq.
com/s/p-UTs_D6RtGUt5a4b5V7GQ
